Rohit Aggarwal, MD, MS
Rohit Aggarwal, MD, MS
Professor of Medicine
Medical Director, Arthritis and Autoimmunity Center
Division of Clinical Immunology and Rheumatology
Department of Medicine
University of Pittsburgh
Dr. Aggarwal is a professor of medicine at University of Pittsburgh and medical director of Arthritis and Autoimmunity Center at University of Pittsburgh Medical Center. He is the co-director of UPMC Myositis Center. His research and clinical areas of interest are clinical and translational research in inflammatory muscle diseases (myositis) and associated interstitial lung disease. He is the past-chair of the medical advisory board of The Myositis Association (TMA) as well as past-chair of the scientific committee of IMACS, which are the largest patient and physician groups working in the field of myositis, respectively.
Dr. Aggarwal is an established independent clinical investigator with significant funding from NIH, foundations and industry and currently leading several collaborations internationally with other key leaders in the world. He has maintained an extremely high publication record and received national and international recognition of his work. He continues to be a leader in disease criteria and outcomes measures in myositis as well as in clinical trials of novel therapeutic agents for myositis. He is currently the principal investigator or member of the steering committee for several international phase 2/3 clinical trials in the area of myositis and associated ILD. Dr. Aggarwal is also mentoring future generation of rheumatologist with great success and attracting younger rheumatologist towards myositis research for the advancement of the field. Dr. Aggarwal lectures at various international conferences and promotes patient education through his YouTube channel.
Financial relationships
-
Attribution:SelfType of financial relationship:Consulting FeeIneligible company:AlexionDate added:04/04/2024Date updated:08/20/2024
-
Attribution:SelfType of financial relationship:Consulting FeeIneligible company:ANI PharmaceuticalsDate added:04/04/2024Date updated:08/20/2024
-
Attribution:SelfType of financial relationship:Consulting FeeIneligible company:ArgenxDate added:04/04/2024Date updated:08/20/2024
-
Attribution:SelfType of financial relationship:Consulting FeeIneligible company:ArtasomeDate added:04/04/2024Date updated:08/20/2024
-
Attribution:SelfType of financial relationship:Consulting FeeIneligible company:AstraZenecaDate added:04/04/2024Date updated:08/20/2024
-
Attribution:SelfType of financial relationship:Consulting FeeIneligible company:Boehringer IngelheimDate added:04/04/2024Date updated:08/20/2024
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:Boehringer IngelheimDate added:04/04/2024Date updated:08/20/2024
-
Attribution:SelfType of financial relationship:Consulting FeeIneligible company:Bristol Myers-SquibbDate added:04/04/2024Date updated:08/20/2024
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:Bristol Myers-SquibbDate added:04/04/2024Date updated:08/20/2024
-
Attribution:SelfType of financial relationship:Consulting FeeIneligible company:Cabaletta BioDate added:04/04/2024Date updated:08/20/2024